摘要
目的研究姜黄素衍生物FM0807的抗肿瘤活性。方法采用四甲基偶氮唑蓝(MTT)法检测FM0807对多种肿瘤细胞生长的抑制作用,并计算IC50;建立S180小鼠移植肿瘤模型并进行体内实验,观察尾静脉和口服两种途径给予FM0807后体内抗肿瘤效果。结果体外抗肿瘤研究表明,FM0807对CA46、HELA、SGC7901、SMMC7721、SW1116等多种人肿瘤细胞均有生长抑制作用,IC50分别为9.20μmol.L-1,20.80μmol.L-1,22.90μmol.L-1,37.54μmol.L-1,44.73μmol.L-1。体内抗肿瘤研究表明,FM0807对S180小鼠移植性肿瘤有明显的抑制作用;200mg/(kg.d)口服给药,抑瘤率32.17%;尾静脉给药,抑瘤率达56.5%。结论 FM0807体内外均有较强抗肿瘤作用。
OBJECTIVE To evaluate the antitumor effect of FM0807 in vitro and in vivo. METIlODS The MTT assay was used to examine the growth arrest of a variety of tumor cells by FM0807. The S180 mouse tumor xenograft models were established and antitumor effect of FM0807 given by tail vein injection was measured. RESULTS FM0807 remarkably inhibited the proliferation of many kinds of tumor cells.The ICs0 values to CA46, HELA, SGC7901, SMMC7721, SWlll6 were 9.20μmol·L-1, 20.80μmol·L-11, 22.90/Lmol . I.-1, 37.54μmol·L-1 , 44.73μmol·L-1. FM0807 showed significant inhibitory effect on S180 mouse tumor xenograft models, the inhibitory rates of FM0807 given by tail vein injection were 56.5 % .CONCLUSION FM0807 was able to inhibit potently the growth of the tumor cells in vitro and in vivo.
出处
《海峡药学》
2011年第10期37-40,共4页
Strait Pharmaceutical Journal
基金
福建省科技重点项目(2009Y0025)
福建省产业技术开发项目(闽发改高技〔2008〕264号)
